BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15078000)

  • 21. Comparative activities of beta-lactam antibiotics and quinolones for invasive Streptococcus pneumoniae isolates.
    Oncü S; Punar M; Eraksoy H
    Chemotherapy; 2004 Jun; 50(2):98-100. PubMed ID: 15211085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of DW286 against Streptococcus pneumoniae.
    Park HS; Jung SJ; Choi DR; Kwak JH
    Int J Antimicrob Agents; 2010 Sep; 36(3):230-3. PubMed ID: 20627463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation].
    Mikamo H; Tanaka K; Watanabe K
    Jpn J Antibiot; 2006 Dec; 59(6):468-73. PubMed ID: 17334064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of clarithromycin against penicillin-susceptible and penicillin-resistant strains of Streptococcus pneumoniae in a pharmacodynamic simulation model.
    Fuentes F; Sevillano D; Balcabao IP; Gómez-Lus ML; Prieto J
    J Chemother; 2000 Dec; 12(6):495-8. PubMed ID: 11154032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
    Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae.
    Stein GE; Schooley S
    Diagn Microbiol Infect Dis; 2001 Mar; 39(3):181-5. PubMed ID: 11337186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae.
    Morrissey I; Tillotson G
    J Antimicrob Chemother; 2004 Feb; 53(2):144-8. PubMed ID: 14729748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
    MacGowan AP; Bowker KE
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1096-100. PubMed ID: 12604547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
    Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
    East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae.
    Lacy MK; Owens RC; Xu X; Nicolau DP; Quintiliani R; Nightingale CH
    Int J Antimicrob Agents; 1998 Nov; 10(4):279-83. PubMed ID: 9916901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
    Clark CL; Kosowska-Shick K; Ednie LM; Appelbaum PC
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4196-201. PubMed ID: 17876003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis.
    Cottagnoud P; Acosta F; Cottagnoud M; Täuber MG
    Antimicrob Agents Chemother; 2002 May; 46(5):1607-9. PubMed ID: 11959614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.
    Calvo A; Giménez MJ; Alou L; Gómez-Lus ML; Aguilar L; Prieto J
    Int J Antimicrob Agents; 2002 Aug; 20(2):144-6. PubMed ID: 12297365
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae.
    Owens RC; Bhavnani SM; Ambrose PG
    Diagn Microbiol Infect Dis; 2005 Jan; 51(1):45-9. PubMed ID: 15629228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.